Novo Nordisk (NVO) announced Friday that its popular ... at a higher dose of 7.2 mg in a late-stage trial. Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that ...

After Novo Nordisk (NVO) reported results from its Phase ... BofA analyst Sachin Jain called the data “a double edged sword.” The high-dose results lift the efficacy of semaglutide as ...

and the preliminary results do not appear to favor Novo Nordisk whatsoever. Per the partial data released from that phase 3b clinical trial, over 72 weeks of once-weekly treatment with either ...

After Novo Nordisk (NVO) reported results from its Phase ... The firm, which believes the data highlights the potential superiority of Viking’s dual GLP-1/GIP receptor agonist VK2735 over ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.

Novo Nordisk's GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications.Seana Smith and Brad Smith ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...

The leaders of major Danish companies, including the CEO of Ozempic-maker Novo Nordisk, have met with the Danish Prime Minister after being summoned to discuss the country’s ongoing spat with ...

Get Wall Street's Hottest Chart Every Morning On Friday, Novo Nordisk A/S NVO released headline results from the STEP UP Phase 3b trial in the global STEP program. Semaglutide 2.4 mg is marketed ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other firms that took a hit on Friday. Wall Street’s main indices all finished in the green ...

Shares in Novo Nordisk were already down before the publication of the list due to new obesity data but fell further on the release and traded down 4.6%. "Novo Nordisk remains opposed to ...